SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sperax is redefining financial autonomy through programmable agents that manage capital, optimize yield, and protect against risk, all transparently on-chain. Founded in 2019, Sperax is backed by leading investors including Jump Trading, Polychain Capital, Amber Group. Sperax offers a new standard in automated, user-driven finance.  The SperaxOS ecosystem is powered by USDs and SPA on Arbitrum, BNB Chain, and other EVM networks. Anchored by two native assets: USDs, a gas-free, auto-yield stablecoin backed by on-chain collateral, and SPA, the governance and value-capture token. Sperax builds open-source tools that turn idle capital into self-optimizing portfolios.  SperaxOS is a cross-chain financial operating system where AI-driven smart agents automate everything from yield farming to payroll, and Demeter, a no-code platform for launching liquidity farms. USDs automatically rebases yield to holders, while SPA lets users register agents, earn protocol fees, and vote on upgrades. Battle-tested through multiple market cycles: Sperax offers individuals, DAOs, and fintechs a borderless toolkit for passive income, risk-managed investing, and fully automated treasury operations, all governed on-chain by its community.

Sperax

Sperax (SPA) is trending due to high anticipation for its SperaxOS launch, which is set to benefit from the recently enacted GENIUS Act by offering a compliant, USD-pegged stablecoin (USDS). This development, coupled with new exchange listings and unusually high trading volume, is fueling community belief in its undervalued status and potential for significant long-term growth.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

Bittensor (TAO) is trending as its recent halving event underscores its scarce 21 million token supply, driving community discussion around its potential as the "Bitcoin of AI" and a foundational decentralized intelligence infrastructure. Growing institutional interest and active subnet development further highlight its long-term value in the evolving AI landscape.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as the market's indiscriminate software sector sell-off, fueled by AI disruption fears, has pushed the stock lower despite strong fundamentals and its OpenAI partnership. Community discussion centers on the company's proprietary data moat and consistent earnings beats, with many viewing current prices as a significant buying opportunity ahead of anticipated results.

TOSHI

Toshi is trending as the community eagerly anticipates a breakout, actively discussing bullish chart formations like the "cup and handle" and noting a significant increase in volume. As a key meme coin within the Base ecosystem, many believe it's poised for a substantial move amid broader market sentiment for altcoins.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic (LUNC) is a top trending crypto as its community discusses a potential major comeback, driven by the recent sentencing of Do Kwon, continued token burns, and ongoing development of new ecosystem projects like LUNCVERSE.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital Holdings is trending after Morgan Stanley initiated an "Underweight" rating and low price target, alongside news of regulatory delays stalling its key French acquisition and AI pivot. The community is actively discussing persistent management criticism, dilution concerns, and MARA's continued underperformance relative to Bitcoin and other mining peers.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is drawing considerable attention following the SEC's dismissal of its lawsuit and a new partnership with AT&T to expand mobile network coverage. This has sparked community discussion about the network's future growth and the recent tokenomics shift consolidating rewards to HNT.

ProShares Trust - ProShares Ultra Semiconductors 2X Shares

ProShares Ultra Semiconductors

ProShares Ultra Semiconductors ($USD) is trending due to robust growth across the semiconductor sector, fueled by the relentless demand for AI compute, with investors actively discussing its strong leveraged performance driven by key industry players.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is trending amidst intense buyout speculation, fueled by strategic interest from major pharmaceutical companies and notable institutional share accumulation, which many in the community interpret as a sign of impending acquisition despite persistent frustration over management's prolonged silence on the promising AUR200 pipeline and core drug Lupkynis.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is trending as UBS substantially increased its long-term lithium price forecast, alongside the company's announcement of a high-value lithium fines sale and clarification that mining operations are resuming, driving bullish sentiment across the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) Insider Sells 5,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of the business's stock in a transaction that occurred on Friday, February 6th. The stock was...

Candriam S.C.A. Raises Stock Position in Enliven Therapeutics, Inc. $ELVN

Candriam S.C.A. grew its holdings in shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 46.3% during the 3rd quarter, according to its most recent filing with the Securities and...

Enliven Therapeutics (NASDAQ:ELVN) Insider Sells $145,200.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 5,000 shares of the company's stock in a transaction dated Friday, February 6th. The stock was sold at an...

Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year High - What's Next?

Enliven Therapeutics (NASDAQ:ELVN) Hits New 12-Month High - Here's What Happened...

Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k

Key PointsEnliven Therapeutics' Chief Scientific Officer sold 20,000 indirect shares for a total of approximately $535,100 on Jan. 20, 2026, at a weighted average price of around $26.75 per share...

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the five analysts that are presently covering the stock, Marketbeat...

Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) Director Richard Heyman sold 1,230 shares of the business's stock in a transaction dated Tuesday, January 20th. The stock was sold at an...

Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 20,000 shares of the company's stock in a transaction on Tuesday, January 20th. The stock was sold at an...

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4% - Should You Buy?

Enliven Therapeutics (NASDAQ:ELVN) Trading Up 7.4% - Should You Buy...

Joseph Lyssikatos Sells 41,302 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) insider Joseph Lyssikatos sold 41,302 shares of the business's stock in a transaction that occurred on Thursday, January 8th. The shares...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

ELVN
Enliven Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest ELVN News

ELVNEnliven Therapeutics Inc